SBBP
Strongbridge Biopharma plc
Set alert
52-week range unavailable
- Open
- 1.96
- Prev close
- 2.00
- Mkt cap
- 135.66M
- Vol
- 684.68K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.96
- High
- 2.05
- Forward P/E
- -11.76
- Beta
- 1.60
- Short ratio
- 1.40
- Inst. own
- 63.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2021
- 50-d avg
- 2.14
- 200-d avg
- 2.48
- 1y target
- 5.00
Key statistics
- Market cap
- 135.66M
- Enterprise value
- 90.57M
- Trailing P/E
- 0.00
- Forward P/E
- -11.76
- PEG ratio
- -0.33
- Price / sales
- 3.91
- Price / book
- 3.05
- EPS (TTM)
- -0.625
- Beta
- 1.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -115.67%
- Revenue (TTM)
- 34.72M
- Revenue growth
- 29.40%
- Free cash flow
- -10.53M
- Total cash
- 63.77M
- Total debt
- 18.68M
- Return on equity
- -87.06%
- Shares outstanding
- 67.83M
- Short % of float
- 0.68%
- 50-day average
- 2.14
- 200-day average
- 2.48
Analyst view
Consensus: buy
- Target (low)
- 3.25
- Target (mean)
- 5.00
- Target (high)
- 8.00
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 4, 2021
Expected Nov 4, 2021. Consensus EPS estimate -0.08.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2021 | Sep 1, 2021 | -0.09 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.10 | — | — | — |
| May 12, 2021 | Mar 1, 2021 | -0.10 | — | — | — |
| Mar 3, 2021 | Dec 1, 2020 | -0.13 | — | — | — |
| Oct 29, 2020 | Sep 1, 2020 | -0.15 | — | — | — |
| Aug 4, 2020 | Jun 1, 2020 | -0.20 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 25, 2021 | Craig-Hallum | down | Buy | Hold |
| May 25, 2021 | JMP Securities | down | Outperform | Market Perform |
| Oct 30, 2020 | HC Wainwright & Co. | main | — | Buy |
| Mar 3, 2020 | Craig-Hallum | init | — | Buy |
| Feb 26, 2020 | Oppenheimer | main | — | Outperform |
| Sep 25, 2019 | Evercore ISI Group | init | — | Outperform |
About Strongbridge Biopharma plc
As of October 5, 2021, Strongbridge Biopharma plc was acquired by Xeris Pharmaceuticals, Inc. Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- strongbridgebio.com
News
- Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma
- Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.
- Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.
- Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.
- Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
- Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris
- Strongbridge Biopharma (SBBP) Reports Q2 Loss, Tops Revenue Estimates
- Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Earnings Scheduled For August 5, 2021
- Strongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statement
Your note
Sign in to keep a note on SBBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHEN FREDRIC J | Officer | Stock Award(Grant) | Jan 6, 2021 | 218,934 |
| GILL DAVID N. | Director | Stock Award(Grant) | May 17, 2021 | 95,821 |
| HERMANSEN STEINEGER HILDE | Director | Stock Award(Grant) | May 17, 2021 | 82,021 |
| JOHNSON JOHN H | Chief Executive Officer | Stock Award(Grant) | Jan 6, 2021 | 1,013,150 |
| KOLLENDER RICHARD S | President | Stock Award(Grant) | Mar 2, 2021 | 327,500 |
| KONG GARHENG | Director | Stock Award(Grant) | May 17, 2021 | 81,756 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Caxton Corporation | 11.92% | 8,083,442 | 24.01M | Jun 29, 2021 |
| NEA Management Company, LLC | 6.11% | 4,141,308 | 12.30M | Jun 29, 2021 |
| Stonepine Capital Management, LLC | 4.87% | 3,305,617 | 9.82M | Jun 29, 2021 |
| Rubric Capital Management LP | 3.97% | 2,695,764 | 8.01M | Jun 29, 2021 |
| Vanguard Group, Inc. (The) | 3.24% | 2,200,172 | 6.53M | Jun 29, 2021 |
| Morgan Stanley | 2.89% | 1,957,351 | 5.81M | Jun 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.03% | 1,378,096 | 4.09M | Jun 29, 2021 |
| Vanguard Extended Market Index Fund | 1.02% | 688,709 | 2.05M | Jun 29, 2021 |
| DFA U.S. Small Cap Series | 0.43% | 292,251 | 698.48K | Jul 30, 2021 |
| Fidelity Extended Market Index Fund | 0.39% | 264,044 | 594.10K | Aug 30, 2021 |
| iShares Micro Cap ETF | 0.19% | 126,227 | 284.01K | Aug 30, 2021 |
| Principal U.S. Small Cap Multi Factor Index ETF | 0.14% | 94,305 | 212.19K | Aug 30, 2021 |